White Papers, Case Studies, Reports
Medable enables >90% eCOA adherence in vaccine trial
A leading biotech company came to Medable looking to conduct a vaccine trial. They were concerned that their trial’s participant population of persons aged 50+ years may be hesitant to use the sponsors’ chosen eCOAtrial technology, would not be engaged in the study, and therefore may not provide consistent trial data.
Learn how we drove success for them, including >90% eCOA adherence.
Tufts CSDD Impact report: Decentralized and hybrid trials deliver greater ROI than traditional trials
The Tufts Center for the Study of Drug Development completed an analysis of its financial modeling study of decentralized clinical trials using real data from Medable-enabled studies. These findings net financial benefits ranging from 5x for Phase II and 13x for Phase III trials, equating to roughly $10 million ROI and $39 million ROI, respectively.
White paper: Why eConsent primes patients and studies for success
Read this white paper to learn how eConsent's flexibility helps you educate and retain patients worldwide, regardless of signature requirements, and how to implement it across your organization.
White paper: Tips for tailoring eConsent for optimal patient centricity.
Use a consent experience that’s designed to meet the needs of patients, while educating and engaging them each step of the way. Read our free white paper to learn eConsent tips from patients themselves, and improve your patient retention.
White paper: The foundations of decentralized clinical trials
Understand the benefits of web-enabled research tools and how they work.
White paper: The building blocks of DCT. How to create a seamless experience across eConsent, eCOA and more
Combining multiple market solutions at the site level can result in a negative experience due to different processes, login credentials, and redundant training. A unified DCT platform that works seamlessly with other core clinical systems to streamline workflows and simplify key trial processes.